The Group ended FY2021 with record adjusted profits and a net cash balance of £20.3m with management successfully disposing of Peter Brotherhood in March 2021 for an enterprise value of £35m, representing a fourfold return on the original investment in September 2017. The Group enters FY2022E in robust shape with important in-year and post-period new orders that cover c.85% and c.40% of FY2022E and FY2023E expected revenues. Significant investment is being directed to the refocused Medical divis ....
